WHO ICTRP trial
Can Empagliflozin improve the structure of the heart in those with pre-Heart…
EUCTR2022-002650-48-IE · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2022-002650-48-IE |
|---|---|
| Public title | Can Empagliflozin improve the structure of the heart in those with pre-Heart Failure and is it feasible to improve physical activity by using mHealth? |
| Scientific title | The impact of Empagliflozin on Left atrIal Volume and the feasibility of using Fitbit and mHealth to prescribe Exercise in non-diabetic Pre- Heart Failure (ELIVE pre-HF Study) |
| Primary sponsor | University College Dublin |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Ireland |
| Conditions | pre-heart failure with preserved ejection fraction MedDRA version: 20.1 Level: LLT Classification code 10076396 Term: Heart failure with preserved ejection fraction System Organ Class: 100000004849 ;Therapeutic area: Diseases [C]… |
| Interventions | Trade Name: Jardiance Pharmaceutical Form: Tablet INN or Proposed INN: Empagliflozin CAS Number: 864070-44-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- |
| Registration date | Jan 17, 2023 |
| Target size | 100 |
| Secondary IDs | UCDCRC/22/02 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: